Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

NCT ID: NCT00602784

Last Updated: 2012-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-11-30
• Study Completion Date: 2004-09-30

Brief Summary

The objectives are

1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine.

2. to document virological (HCV-RNA) and biochemical (ALT) responses following immunization with HCV antigen peptide vaccine with polyarginine.

3. to assess the safety of immunization with HCV antigen peptide vaccine with polyarginine.

Detailed Description

This is a double blind, randomized, parallel group, controlled, multicenter phase II study.

60 patients will be enrolled and assigned to one of the 5 dose or control groups. Each study group will include 8 patients.

Each patient will receive a total of 6 injections according to the dose of the assigned study group. The injections will be administered subcutaneously in the upper arm once every four weeks for 5 months, i.e. at days 1, 29, 57, 85, 113 and 141.

The volume of each injection will be 0.5 ml in all groups.

Conditions

Chronic Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

IC41-B-01/02

peptide dose 0.00 mg, polyarginine dose 2.00 mg

Group Type: EXPERIMENTAL

IC41

Intervention Type: BIOLOGICAL

IC41-C-01/02

peptide dose: 5.00 mg, polyarginine dose: 0.00 mg

Group Type: EXPERIMENTAL

IC41

Intervention Type: BIOLOGICAL

IC41-G-01/02

peptide dose: 2.50 mg, polyarginine dose: 1.25 mg

Group Type: EXPERIMENTAL

IC41

Intervention Type: BIOLOGICAL

IC41-H-01/02

peptide dose: 2.50 mg, polyarginine dose: 2.00 mg

Group Type: EXPERIMENTAL

IC41

Intervention Type: BIOLOGICAL

IC41-K-01/02

peptide dose: 5.00 mg, polyarginine dose: 2.00 mg

Group Type: EXPERIMENTAL

IC41

Intervention Type: BIOLOGICAL

Interventions

IC41

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Diagnosis of chronic hepatitis C
• Non-response to or relapse from primary standard HCV therapy
• HLA A2 positive
• HCV-RNA positive
• HCV antibodies positive
• Liver biopsy within 30 months prior to inclusion
• Hematology and biochemistry laboratory results within the limits normally expected for the patient population (liver values maximal 5 times the upper limit of normal)
• Male and female
• From 18 to 65 years
• Written informed consent obtained prior to study entry

Exclusion Criteria

• Any degree of liver cirrhosis or fibrosis of Ishak score ≥ 4 (for grading table, see APPENDIX 2: The Ishak Modified Hepatic Activity Index (HAI))
• Any liver disease other than hepatitis C
• History of autoimmune disease
• Immunodeficiency including post-organ-transplantation
• HIV infection
• Immunosuppressive therapy
• Any acute infections within 4 weeks prior to inclusion
• History of severe hypersensitivity reactions, anaphylaxis or atopy
• Diabetes mellitus, severe cardiopulmonary disorders, history of malignancy in the past 5 years
• Active or passive vaccination within 2 months prior to enrolment, and concomitant vaccination throughout the study period
• Pregnancy or lactation
• Unreliable contraception
• Alcohol consumption
• Drug abuse or addiction within 12 months prior to inclusion
• Participation in a methadone program
• Participation in another study within 1 month prior to enrolment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Valneva Austria GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erich Tauber, M.D.

Role: STUDY_DIRECTOR

Valneva Austria GmbH

Other Identifiers

IC41-201

Identifier Type: -

Identifier Source: org_study_id